Since its listing on the London Stock Exchange in 1994, CortecsInternational, which has had a primary listing on the Australian Stock Exchange since 1986, has increased its capital base substantially, with new capital emanating from the UK and other European investors.
In addition, most of the firm's business is carried out in the UK, which has prompted the group to establish a new firm, Cortecs plc, in the UK as its parent and holding company, with a primary listing on the LSE, in order to maximize its opportunities, it has said. Cortecs plc ordinary shares will also be traded on the ASE and the Nasdaq.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze